Pay in 4 interest-free payments of $5.66 Learn more
Ships within 48 hours · Estimated delivery Oct 4 - Oct 9
It is known that the CV protection effect of GLP-1RAs have been proven through eight large-scale clinical studies, including Evaluation of LIXisenatide in Acute coronary syndrome (ELIXA) [66], LEADER [44], Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN)-6 [67], Exenatide Study of Cardiovascular Event Lowering (EXSCEL) [68], Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes) [69], Researching Cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) [70], Peptide Innovation for Early Diabetes Treatment (PIONEER) 6 [67,71], and AMPLITUDE-O [51]
Siemes H, Nau H, Schultze K, Wittfoht W, Drews E, Penzien J, Seidel U: Valproate (VPA) metabolites in various clinical conditions of probable VPA-associated hepatotoxicity
PMID: 33924182
T., & Schneider, C
US$ 25.49
US$ 25.27
US$ 26.85
US$ 21.04
US$ 21.72
US$ 25.77
US$ 24.68
US$ 21.79
